Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 4, keine Gesamtzahl für „Mate“
Suchtreffer
Begriffe & Kennungen
Benepali · 4.8 · In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with etanercep
Eintrag öffnenBenepali · 4.8 · In controlled trials in patients with plaque psoriasis, approximately 13.6% of patients treated with etanercep
Eintrag öffnenBenzocain
Eintrag öffnenBeschichtete Materialien, biokompatible
Eintrag öffnenBetmiga · 4.8 · 32 MedDRA Common Uncommon Rare Very rare Not known System organ (cannot be class estimated from the available
Eintrag öffnenBetmiga · 4.8 · 8 MedDRA Common Uncommon Rare Very rare Not known System organ (cannot be class estimated from the available d
Eintrag öffnenBewegliche Bücher
Eintrag öffnenBibliotheksmaterialien
Eintrag öffnenBiktarvy · 4.5 · Bictegravir inhibits organic cation transporter 2 (OCT2) and multidrug and toxin extrusion transporter 1 (MATE
Eintrag öffnenBimzelx · 4.8 · Approximately 31% of patients with psoriatic arthritis treated with bimekizumab at the recommended dosing regi
Eintrag öffnenBimzelx · 4.8 · Approximately 44% of patients with AS treated with bimekizumab up to 52 weeks at the recommended dosing regime
Eintrag öffnenBimzelx · 4.8 · Approximately 45% of plaque psoriasis patients treated with bimekizumab up to 56 weeks at the recommended dosi
Eintrag öffnenBimzelx · 4.8 · Approximately 57% of patients with nr-axSpA treated with bimekizumab up to 52 weeks at the recommended dosing
Eintrag öffnenBimzelx · 4.8 · Approximately 59% of HS patients treated with bimekizumab up to 48 weeks at the recommended dosing regimen (32
Eintrag öffnenBinocrit · 4.8 · Frequency estimate: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1 000 to < 1/100); rare (≥
Eintrag öffnenBiomaterialbanken
Eintrag öffnenBiomedizinische und dentale Materialien
Eintrag öffnenBiometrische Authentifizierung
Eintrag öffnenBiomimetische Materialien
Eintrag öffnenBiopoin · 4.8 · Summary of the safety profile Approximately 9% of patients can be expected to experience an adverse reaction.
Eintrag öffnen